NewAmsterdam Pha SEC Filings

NewAmsterdam Pharma Company N.V. reported a Rule 144 notice for a sale of 6,000 ordinary shares. The sale was reported by Johannes Jacob Pieter Kastelein with a transaction date of 01/05/2026 and proceeds shown as $199,500.

NewAmsterdam Pharma Company N.V. files its annual report describing a late-stage biopharma business built around obicetrapib, an oral CETP inhibitor aimed at lowering LDL cholesterol in high‑risk cardiovascular patients who are not at goal on statins.

Multiple Phase 3 trials (BROADWAY, BROOKLYN and TANDEM) met primary and secondary endpoints with statistically significant LDL-C reductions and safety broadly comparable to placebo. A large cardiovascular outcomes trial, PREVAIL, is underway to evaluate major adverse cardiovascular event benefit.

The company has partnered with Menarini in most of Europe, receiving a €115 million upfront payment, committed €27.5 million R&D funding and potential milestones up to €863 million, plus tiered royalties. EMA, UK and Swiss regulators are reviewing marketing applications, with decisions anticipated in the second half of 2026. A broad patent estate could protect obicetrapib and combinations into the 2040s, and early work is exploring its use in Alzheimer’s disease.

NewAmsterdam Pharma reported full year 2025 results and highlighted progress advancing its cholesterol drug obicetrapib. Revenue was $22.5 million, down from $45.6 million in 2024, while the net loss narrowed to $203.8 million from $241.6 million as R&D expenses declined.

Cash, cash equivalents and marketable securities totaled $728.9 million at December 31, 2025, which the company expects will fund operations through the PREVAIL cardiovascular outcomes readout and, if approved, support a potential U.S. launch. Marketing applications for obicetrapib and a fixed-dose combination with ezetimibe have been accepted in Europe, the UK and Switzerland, with decisions anticipated in the second half of 2026.

The company is running three Phase 3 trials—PREVAIL, REMBRANDT and RUBENS—and plans to start a trial of obicetrapib in early Alzheimer’s disease in 2026 following positive Alzheimer’s biomarker data from the BROADWAY study.

NewAmsterdam Pharma Co N.V. received an updated Schedule 13G/A (Amendment No. 3) from investment entities affiliated with Viking Global, disclosing their passive ownership in the company’s ordinary shares.

The Viking-related entities collectively report beneficial ownership of 4,203,567 ordinary shares, representing 3.7% of the outstanding class, based on 113,390,804 ordinary shares outstanding as of October 31, 2025. The shares are held through two main limited partnerships, which directly own 2,817,205 and 1,386,362 ordinary shares, respectively. Key individuals O. Andreas Halvorsen, David C. Ott and Rose S. Shabet are reported as having shared voting and dispositive power over these holdings through their roles in Viking’s general partner and parent entities.

The filing states that the securities were not acquired and are not held for the purpose of changing or influencing control of NewAmsterdam Pharma, indicating a passive investment stance under the 13G framework.

FMR LLC has filed a Schedule 13G reporting beneficial ownership of 6,412,984 shares of Pharma Company NV common stock, representing 5.7% of the class as of the event date. FMR has sole voting power over 6,403,075 shares and sole dispositive power over 6,412,984 shares.

Abigail P. Johnson is also reported as a beneficial owner with sole dispositive power over the same 6,412,984 shares and no voting power. The filing states the shares were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of Pharma Company NV.

NewAmsterdam Pharma Co N.V.’s Chief Accounting Officer Louise Frederika Kooij reported option exercises and share sales in late January 2026. On January 27, 2026, she exercised 39,816 options at an exercise price of $10.90 per ordinary share and acquired the same number of ordinary shares.

That same day she sold 39,816 ordinary shares at a weighted average price of $32.62 per share, leaving 24,353 ordinary shares directly owned afterward. On January 28, 2026, she exercised another 32,612 options at $10.90 per share and acquired 32,612 ordinary shares, then sold 32,612 ordinary shares at a weighted average price of $31.80 per share.

After these transactions, she directly held 24,353 ordinary shares and 73,134 options (options with a $10.90 exercise price and an expiration date of January 1, 2033). The filing notes that the sale prices are weighted averages across multiple trades within the stated price ranges.

NewAmsterdam Pharma Co N.V.’s Chief Accounting Officer, Louise Frederika Kooij, reported multiple option exercises and share sales in January 2026. On January 23, 2026, she exercised options for 38,172 ordinary shares at an exercise price of $10.90 per share, then sold 25,405 shares at a weighted average price of $33.44 and 12,767 shares at a weighted average price of $34.37, all as ordinary shares.

On January 26, 2026, she exercised additional options for 34,400 ordinary shares at $10.90 per share and sold 34,091 shares at a weighted average price of $32.77 and 309 shares at a weighted average price of $33.45. After these transactions, she directly owned 24,353 ordinary shares and held 145,562 options (right to buy) for ordinary shares.

NewAmsterdam Pharma Co N.V.’s Chief Financial Officer, Mayur Ian Somaiya, reported stock option exercises and related share sales. On January 20 and 21, 2026, he exercised options to acquire 60,216 and 39,784 ordinary shares at an exercise price of $9.26 per share. On the same dates, he sold several blocks of ordinary shares, including 39,712, 19,604, and 24,362 shares at prices referenced in ranges from about $30.17 to $34.31 per share, as detailed in the footnotes.

After these transactions, Somaiya directly held 58,382 ordinary shares and 662,814 option-based derivative securities. The filing states that at least one sale transaction was carried out under a Rule 10b5-1 trading plan, and notes that the underlying option was granted on November 1, 2023 with vesting over four years, subject to continued service.